Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talnetant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 known ✓ | P29371 | 20/20 | 0.96 |
| ▸ | TACR2 | P21452 | 6/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | TACR1 | P25103 | 1/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talnetant SCHEMBL74221 | 0.98 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL29604291 | 0.98 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL74220 | 0.98 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL6449764 | 0.98 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL29390363 | 0.98 | TACR3 (1.00) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL5154081 | 0.97 | TACR3 (0.98) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL29407582 | 0.97 | TACR3 (0.98) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| Talnetant SCHEMBL27458094 | 0.97 | TACR3 (0.98) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14094490 | 0.94 | TACR3 (0.88) | TACR3TACR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14094501 | 0.91 | TACR3 (0.82) | TACR3TACR2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299100-B1 | METHOD OF TREATING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIV ROCHESTER (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| EP-1299100-A4 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIV ROCHESTER (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030236237-A1 | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist | GUTTUSO THOMAS J (US) | 2003-12-25 | — | — | US | disclosed |
| EP-1299100-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | THE UNIVERSITY OF ROCHESTER (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020016283-A1 | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist | UNIVERSITY OF ROCHESTER | 2002-02-07 | — | — | US | disclosed |
| WO-2001095904-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIVERSITY OF ROCHESTER (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010543-A1 | Compositions and methods for treating gastrointestinal hypomotility and associated disorders | HTR3A, HNMT, HTR3B | TACR3 227/4885TACR2 201/4885CYP1A2 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.